News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its prima ...
Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and...
Assignment of the "-fentrine" stem in the INN attests to RPL554's dual phosphodiesterase inhibitor mechanism of action LONDON...
News) - Biopharmaceutical firm Verona Pharma PLC on Monday said a phase two clinical trial of its RPL554 dry powder in ...
Delivery via inhalers could dramatically expand clinical utility and commercial opportunity for RPL554 LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE...
News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased fi ...
Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing...
News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating th ...
Enrollment complete ahead of schedule Top line data expected in January 2019 LONDON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:...
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable pharmacokinetic...
LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a...
LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.